This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PIAS1 / E3 SUMO-protein ligase PIAS1 · IHC design guide
Design Immunohistochemistry for PIAS1
Expect nuclear PIAS1 staining in paraffin-section IHC (HPA tissue IHC). This guide covers fixation, controls and scoring, including the PIAS2/3 cross-reactivity of M01707 (datasheet M01707).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PIAS1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Widespread nuclear signal across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M01707) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | M01707 also detects PIAS2/3; signal is not PIAS1-specific (datasheet M01707) | |
| Regulation | IFNA1-linked binding; intensity unknown (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unresolved (UniProt) |
Section 1
Recommended PIAS1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol uses EDTA retrieval (datasheet: pH 8.0). These published PIAS1 protocols provide three chromogenic IHC examples (PMC4322998; PMC10184048; PMC5777733).
| Sample | Paraffin-embedded human colon adenocarcinoma tissue; fixative not specified (datasheet M01707) |
| Fixation | Image fixative and duration unreported (datasheet M01707); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M01707); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M01707) |
| Primary antibody | Rabbit monoclonal (clone ABFA-16) anti-PIAS1, 1:50 (datasheet M01707) |
| Primary incubation | Overnight at 4 °C (datasheet M01707) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M01707) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PIAS1-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: M01707). The published protocols specify citrate retrieval where reported (PMC10184048; PMC5777733).
Section 2
What Is the Expected PIAS1 Staining Pattern?
PIAS1 should appear mainly in nuclei across many cell types in paraffin sections; HPA describes ubiquitous nuclear expression with Supported tissue IHC reliability, meaning staining is consistent with RNA expression (HPA tissue IHC). High staining is reported in adipocytes, glandular cells, hematopoietic cells and selected brain cells (HPA tissue IHC). PIAS1 has no transmembrane segment, so a membrane pattern is unexpected (UniProt O75925 topology).
| Nuclear chromogen in adipocytes, glandular cells or hematopoietic cells, with limited background. | This fits the reported ubiquitous nuclear pattern and High staining in these cell types (HPA tissue IHC). Judge each cell's nucleus against its surrounding cytoplasm and nearby unstained areas; intensity can vary across cells. A counterstain helps identify nuclei, while the chromogen shows where antibody-associated signal appears (general IHC practice). |
| Strong membrane-only or broadly cytoplasmic staining with little nuclear signal. | Treat this as a localisation mismatch: PIAS1 is nuclear, including nuclear speckles and PML bodies, and lacks a transmembrane segment (UniProt O75925). HPA tissue IHC reports a ubiquitous nuclear pattern. UniProt also lists conditional cytoskeletal redistribution, so limited extranuclear signal alone does not establish an artefact (UniProt O75925 subcellular location). |
| Strong signal in cells expected to stain weakly, especially smooth muscle cells. | HPA reports Low staining in smooth muscle cells and lists no negative tissue (HPA tissue IHC). Disproportionately strong signal there warrants a specificity check, including cross-reactivity; widespread chromogen outside cellular structures can also reflect endogenous detection activity (general IHC practice). Do not classify smooth muscle as a definitive negative control. |
| Diffuse haze across tissue and blank spaces, obscuring nuclear boundaries. | This does not match the nuclear distribution reported for PIAS1 (HPA tissue IHC). Possible general IHC causes include insufficient blocking, concentrated primary antibody, inadequate washing or endogenous enzyme activity. Compare a no-primary control and inspect whether the haze persists without primary antibody before assigning it to PIAS1 (general IHC practice). |
| No nuclear signal in a section containing a documented High-staining cell population. | Adipocytes and bone-marrow hematopoietic cells are among HPA's High examples (HPA tissue IHC). An absent signal there makes the run inconclusive; check tissue identity, primary-antibody application, retrieval and detection controls (general IHC practice). HPA's tissue pattern does not identify a PIAS1-specific fixation failure. |
💡Expected PIAS1 appearanceCall a result positive when interpretable nuclei show clear chromogen in an HPA High cell population, such as adipocytes or hematopoietic cells; predominant membrane-only staining or diffuse haze is suspect (HPA tissue IHC; UniProt O75925 topology).
| Nuclear localisation and topology | PIAS1 is nuclear, including speckles and PML bodies, with no transmembrane segment (UniProt O75925). Score nuclear signal first; cytoplasmic chromogen alone cannot confirm the expected tissue IHC pattern (HPA tissue IHC). |
| Cell population and comparator | HPA reports High staining in several named cell types, Low staining in smooth muscle cells, and no negative tissues (HPA tissue IHC). Use identified High populations as positive comparators; interpret a weak smooth-muscle result as relative, not absolute absence. |
| Antibody and application evidence | CAB012304 has Supported IHC status; HPA073610 has no listed IHC status in the supplied antibody record (HPA antibodies). These labels describe antibody-specific evidence and do not transfer validation from one antibody to another. |
| IF/ICC: should cytosolic signal be expected? | HPA reports mainly nucleoplasmic PIAS1 with additional cytosolic localisation, but marks both ICC-IF locations uncertain (HPA subcellular ICC-IF). That observation can guide interpretation of an IF image; it does not replace the nuclear expectation for tissue IHC. |
| Situation | Likely cause | Next action |
|---|---|---|
| High-population nuclei remain blank. | The run may have failed at tissue selection, primary-antibody application or detection; HPA reports High staining in adipocytes and hematopoietic cells (HPA tissue IHC). | Verify the cell population on the counterstained section, then check the run's positive control, reagent sequence and chromogen development (general IHC practice). |
| Only membranous staining appears. | A membrane-only pattern conflicts with PIAS1's lack of a transmembrane segment and its nuclear localisation (UniProt O75925). | Review morphology and the no-primary control, then repeat with an IHC-validated antibody if available; CAB012304 carries Supported IHC status in this record (HPA antibodies; general IHC practice). |
| Strong chromogen appears in smooth muscle. | This exceeds HPA's Low smooth-muscle observation and may reflect cross-reactivity or detection background (HPA tissue IHC; general IHC practice). | Compare nearby nuclear staining with a documented High cell population and inspect a no-primary control. A Low HPA call is a relative comparator, not proof that every smooth-muscle nucleus must be blank (HPA tissue IHC). |
| Diffuse staining persists across cells and empty areas. | Nonlocalized signal is inconsistent with the expected nuclear pattern (HPA tissue IHC); residual detection activity or nonspecific reagent binding is possible (general IHC practice). | Check the no-primary control, blocking and wash steps; adjust the primary concentration only after locating the background source (general IHC practice). |
| Nuclear detail is obscured despite visible chromogen. | Heavy chromogen or counterstain can conceal whether signal is truly nuclear (general IHC practice). | Review a lighter development or counterstain condition and compare cell boundaries with an adjacent section; call localisation only where nuclei remain identifiable (general IHC practice). |
| A proposed fix assumes PIAS1 is fixation-sensitive. | Neither the supplied HPA tissue IHC pattern nor UniProt topology establishes a target-specific fixation effect (HPA tissue IHC; UniProt O75925). | Record the fixation and retrieval conditions used, then compare controlled runs if optimisation is needed (general IHC practice). Describe any effect as observed in that workflow rather than established PIAS1 biology. |
Experiment evidence
IHC & IF images showing PIAS1 staining
M01707 · IHCIHC analysis of PIAS1+PIAS2+PIAS3 using anti-PIAS1+PIAS2+PIAS3 antibody (M01707). PIAS1+PIAS2+PIAS3 was detected in a paraffin-embedded sect
M01707 · IHCIHC analysis of PIAS1+PIAS2+PIAS3 using anti-PIAS1+PIAS2+PIAS3 antibody (M01707). PIAS1+PIAS2+PIAS3 was detected in a paraffin-embedded sect
PA2252 · IHCAnti-PIAS1 antibody, PA2252, IHC(P) IHC(P): Rat Testis Tissue
PA2252 · IHCAnti-PIAS1 antibody, PA2252, IHC(P) IHC(P): Rat Brain Tissue
PA2252 · IFAnti-PIAS1 antibody, PA2252, ICC ICC: A549 Cell
A01707 · IFIF analysis of PIAS1 using anti-PIAS1 antibody (A01707). PIAS1 was detected in immunocytochemical section of A431 cells. Enzyme antigen retr
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000033800-PIAS1/tissue/cerebral+cortex#imid_3231816
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000033800-PIAS1/tissue/colon#imid_3272878
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000033800-PIAS1/tissue/liver#imid_3272887
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000033800-PIAS1/tissue/kidney#imid_3272888
HPA · ICC-IF HELHuman Protein Atlas immunofluorescence, HEL, antibody HPA073610; green = PIAS1, blue = nucleus, red = microtubules.
HPA · ICC-IF HELHuman Protein Atlas immunofluorescence, HEL, antibody HPA073610; green = PIAS1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PIAS1 IHC & IF
🧪Run adipose tissue first and assess staining in adipocytes (HPA: High in adipocytes). HPA detects PIAS1 in all 45 scored tissues, so use no-primary and isotype controls for the negative comparison; cells on the positive slide with little or no signal can help assess local background but are not validated PIAS1-negative cells (HPA: no negative tissue rows).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: PIAS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PIAS1 in HEL, HaCaT, U2OS, with annotated localisation: Nucleoplasm (uncertain) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and monoclonal or polyclonal format; and PIAS1-knockout tissue or a validated peptide-block control to test specificity (standard IHC practice). Quench endogenous peroxidase for HRP/DAB detection and inspect lipid-rich adipose sections for nonspecific background (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: A PIAS1-specific fixation window or fixation effect is unreported, and the selected M01707 paraffin-section caption does not state the fixative (caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but it does not establish that retrieval is required for PIAS1 in adipose tissue; the pictured antibody detects PIAS1+PIAS2+PIAS3, so its staining alone cannot establish PIAS1 specificity (caption: EDTA pH 8.0; caption: PIAS1+PIAS2+PIAS3). Whether frozen sections or IF would be easier is unreported for this antibody; lipid-rich adipose sections can show empty vacuoles and background that complicate scoring (standard IHC practice).
HPA tissue IHC evidence for PIAS1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: PIAS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced PIAS1 IHC Tips
PIAS1 staining is mainly nuclear, but the catalog antibody also recognizes PIAS2 and PIAS3; interpret its signal accordingly (UniProt O75925 localization; M01707 caption).
What retrieval should I try first if nuclear staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet M01707). The documented tissue example used this retrieval before 10% goat serum blocking and 1:50 primary antibody overnight at 4°C (M01707 caption). If staining remains weak, adjust heating duration using matched control sections while keeping the buffer and detection steps constant; the caption does not specify a retrieval time (M01707 caption). Compare nuclear signal and tissue preservation across the series, because PIAS1 is predominantly nuclear and the catalog antibody detects PIAS1, PIAS2 and PIAS3 (UniProt O75925 localization; M01707 caption).
Could fixation explain weak PIAS1 staining in my paraffin sections?
Target-specific fixation sensitivity is unknown: the catalog tissue caption describes a paraffin section but does not state its fixative (M01707 caption). Record the actual fixative and fixation duration for each specimen, then compare sections processed with the same pH 8.0 EDTA retrieval and 1:50 primary dilution used in the documented example (M01707 caption). Inspect morphology and nuclear staining together, because damaged sections can make a weak result difficult to interpret; use matched processing controls when assessing any fixation difference (standard IHC practice). Do not infer a PIAS1-specific fixation effect from its nuclear localization or reported modifications (UniProt O75925 localization and modified residues).
How should I assess nuclear, speckled, or cytoplasmic staining?
Score nuclear staining first: tissue IHC reports ubiquitous nuclear expression, while UniProt places PIAS1 in nuclei, nuclear speckles and PML bodies (HPA tissue IHC; UniProt O75925 localization). Use the counterstain to identify intact nuclei, then assess whether puncta lie within them rather than overlying debris or uneven chromogen deposits (standard IHC practice). UniProt also reports cytoskeletal localization under a stated interaction context, and HPA lists cytosolic signal with uncertain localization, so cytoplasmic staining needs independent validation (UniProt O75925 localization; HPA subcellular). The 1:50 catalog antibody recognizes PIAS1, PIAS2 and PIAS3, limiting attribution of any compartment pattern to PIAS1 alone (M01707 caption).
Can this stain distinguish PIAS1 isoforms or modified epitopes?
Do not assign a positive nucleus to a particular PIAS1 isoform: the record lists 3 isoforms, but the supplied tissue caption gives no isoform-specific epitope information (UniProt O75925 isoforms; M01707 caption). The catalog antibody is described as detecting PIAS1, PIAS2 and PIAS3, so its chromogenic signal cannot by itself establish PIAS1-specific expression (M01707 caption). PIAS1 has a SAP region at residues 11–45, a PINIT region at 124–288 and reported phosphorylation sites, but the supplied caption does not locate the antibody epitope (UniProt O75925 domains and modified residues; M01707 caption). Use independently validated specificity controls before interpreting changes as isoform selection or phosphorylation-dependent staining (standard IHC practice).
How can I examine PIAS1 with a cell-type marker by IF?
For the separate IF/ICC assay, multiplex the PIAS signal with a validated marker of the expected cell type and a nuclear stain, then inspect single channels before overlays (standard IF practice). HPA reports high PIAS1 staining in adipocytes among other cell types and mainly nucleoplasmic localization in its subcellular data (HPA tissue IHC; HPA subcellular). Choose spectrally separated fluorophores after checking tissue autofluorescence, and include single-stain controls for bleed-through (standard IF practice). Because PIAS1 has no transmembrane segment and is primarily nuclear, optimize permeabilisation to give antibody access to intracellular epitopes without losing morphology; do not carry over the IHC caption as an IF protocol (UniProt O75925 topology and localization; M01707 caption).
What should I check when DAB staining looks diffuse?
Compare the stained section with a no-primary control to identify signal from the detection system, and examine whether diffuse color follows folds, damaged edges or endogenous peroxidase-rich areas (standard IHC practice). The documented workflow used 10% goat serum, 1:50 primary antibody overnight at 4°C, a peroxidase-conjugated secondary for 30 minutes at 37°C, and DAB development (M01707 caption). Confirm that the general IHC peroxidase-blocking step and washes worked before changing the primary concentration (standard IHC practice). Favor reproducible nuclear signal over diffuse cytoplasmic color, while remembering that the catalog antibody also detects PIAS2 and PIAS3 (HPA tissue IHC; M01707 caption).
How should I score PIAS staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the nuclear compartment before scoring, then report either an H-score from intensity and percentage of positive cells or the percentage of positive nuclei by cell type (standard IHC practice; HPA tissue IHC). Normalize counts to the number of evaluable nuclei in the same annotated region, and keep retrieval, DAB development and image settings consistent across compared sections (standard IHC practice). Exclude folds, necrotic regions and section edges using rules set before scoring, and review matched controls alongside each batch (standard IHC practice). Label the result as PIAS-family staining unless specificity has been established, because M01707 is described as detecting 3 proteins: PIAS1, PIAS2 and PIAS3 (M01707 caption).
How can I distinguish a plausible PIAS1 result from artefact?
A plausible pattern is predominantly nuclear in intact cells, consistent with supported tissue IHC and UniProt localization, but that agreement alone does not identify PIAS1 specifically (HPA tissue IHC; UniProt O75925 localization; M01707 caption). Check cell identity against the counterstain and tissue architecture; HPA reports high staining in adipocytes and low staining in smooth muscle cells (HPA tissue IHC). Treat staining confined to section edges, necrotic areas or no-primary controls as suspect, and assess endogenous peroxidase when interpreting DAB deposits (standard IHC practice). The documented pH 8.0 retrieval supports the staining workflow, while the antibody’s PIAS1, PIAS2 and PIAS3 reactivity limits protein-specific conclusions (M01707 caption).
Boster reagents
Best PIAS1 / E3 SUMO-protein ligase PIAS1 IHC Antibodies
IHC figures cover human colon adenocarcinoma and spleen (M01707 captions), plus rat testis and brain and human placenta (PA2252 captions); IF covers human A431 cells (A01707 caption).
Real IHC data
Anti-PIAS1+PIAS2+PIAS3 Rabbit Monoclonal Antibody
Cat # M01707
Real IHC data
Anti-E3 SUMO-protein ligase PIAS1 PIAS1 Antibody ®
Cat # PA2252
Real IF data
Anti-E3 SUMO-protein ligase PIAS1 PIAS1 Antibody ®
Cat # A01707
M01707 has paraffin-section IHC figures for human colon adenocarcinoma and spleen (M01707 captions), while PA2252 has IHC(P) figures for rat testis and brain and human placenta (PA2252 captions). A01707 has an IF figure for human A431 cells (A01707 caption).
Which to pick: For tissue IHC, choose PA2252 when a PIAS1-labeled reagent is required (PA2252 title and IHC(P) captions); M01707 has a documented 1:50 paraffin-section IHC workflow but recognizes PIAS1, PIAS2 and PIAS3 (M01707 caption). For IF/ICC, A01707 has an A431-cell IF figure at 2 μg/mL (A01707 caption). For human, mouse or rat IHC, both PA2252 and monoclonal M01707 list those species, although the pictured IHC samples establish only the species shown (catalog reactivity; M01707 and PA2252 captions); the paraffin-section captions do not report the fixative (M01707 and PA2252 captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O75925 (PIAS1_HUMAN, E3 SUMO-protein ligase PIAS1).
- Human Protein Atlas. PIAS1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. PIAS1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. PIAS1 antibody validation summary (2 antibodies).
- PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget 2014 — PMC4322998.
- Syringic acid demonstrates an anti-inflammatory effect via modulation of the NF-κB-iNOS-COX-2 and JAK-STAT signaling pathways in methyl cellosolve-induced hepato-testicular inflammation in rats. Biochemistry and biophysics reports 2023 — PMC10184048.
- Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer. Oncotarget 2017 — PMC5777733.
- PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma. Cancers 2025 — PMC12427710.
- PubMed PMID:9724754 — UniProt-cited evidence.
- PubMed PMID:10628744 — UniProt-cited evidence.
- PubMed PMID:19906316 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PIAS1 (E3 SUMO-protein ligase PIAS1). Expected localisation Ubiquitous nuclear tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M01707). Validated IHC antibody: M01707 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colon adenocarcinoma tissue; fixative not specified (datasheet M01707); 2. Fixation: Image fixative and duration unreported (datasheet M01707); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M01707); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M01707); 8. Primary antibody: Rabbit monoclonal (clone ABFA-16) anti-PIAS1, 1:50 (datasheet M01707); 9. Primary incubation: Overnight at 4 °C (datasheet M01707). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: M01707 also detects PIAS2/3; signal is not PIAS1-specific (datasheet M01707); Isoform / epitope: 3 isoforms; epitope coverage is unresolved (UniProt); Regulation: IFNA1-linked binding; intensity unknown (UniProt). Evidence: UniProt O75925, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M01707, PMC4322998, PMC10184048. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PIAS1/immunohistochemistry-ihc-guide.